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Estrogen Stimulates Dimethylarginine
Dimethylaminohydrolase Activity and the Metabolism of
Asymmetric Dimethylarginine
Desmond P. Holden, MRCOG, PhD; Judith E. Cartwright, PhD;
Stephen S. Nussey, FRCP, DPhil; Guy St J. Whitley, PhD
Background—Experimental evidence suggests that estrogens stimulate the production of nitric oxide (NO) by vascular
endothelial cells. This effect has been attributed to increased expression and enzymatic activity of both the constitutive
and inducible isoforms of NO synthase. In this study, we have investigated whether estrogens regulate the metabolism
or release of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase.
Methods and Results—The concentration of ADMA in the plasma of 15 postmenopausal women was 0.7220.04 mol/L
(meanSEM). Two weeks after subcutaneous implantation with estradiol, there was an increase in plasma estradiol
concentration from 0.6930.075 to 0.8187 nmol/L, which was accompanied by a significant fall in plasma ADMA
concentration to 0.5880.03 mol/L (P0.006). Human and murine endothelial cell lines previously cultured in
estrogen-free medium and then exposed to 17-estradiol showed a dose-dependent decrease in the release of ADMA. This
reached statistical significance at 1014 mol/L 17-estradiol and was accompanied by a corresponding increase in the activity
of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme that catalyzes the metabolism of ADMA.
Conclusions—We have demonstrated that estrogens can alter the catabolism and release of ADMA in vitro and reduce the
circulating concentration in vivo. We therefore propose that increased DDAH activity and the subsequent fall in ADMA could
contribute to the positive effect of estrogen on NO synthesis. (Circulation. 2003;108:1575-1580.)
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Significant differences in cardiovascular function and dis-ease have been reported between men and women. The
incidence of coronary heart disease (CHD) in men exceeds
that in women of similar age, whereas CHD among women
rises sharply after the onset of natural or surgically induced
menopause. Many of these effects have been attributed at
least in part to gonadal steroids, in particular estrogen.
Additional support comes from numerous studies using ex-
perimental models.1 Although the concept that estrogen
replacement therapy (ERT) is cardioprotective has been
challenged recently by the negative results of randomized
clinical trials in coronary heart disease,2,3 several retrospec-
tive and cross-sectional studies indicate that women treated
with ERT have improved vascular function and a lower
incidence of CHD.4
Mechanistically, the effects of estrogen on cardiovascular
function have been attributed to favorable changes in plasma
lipid profile, which may account for 25% to 50% of the
protective effects. Direct effects of estrogens on endothelial
function and vascular reactivity as a result of enhanced produc-
tion or activity of several vasoactive compounds including nitric
oxide (NO) have also been reported.5 Estradiol stimulates the
expression of both endothelial NO synthase (eNOS) and induc-
ible NOS (iNOS) in vascular cells5,6 and stimulates NO-
dependent vasodilatation in vivo.7 There is also evidence that
estrogen stimulates eNOS activity directly via the activation of
membrane-associated steroid hormone receptors.8 The mecha-
nisms involved have not been fully elucidated, but there is
evidence that activation of the phosphatidylinositol 3-kinase/Akt
pathway is involved.9,10
Endogenous competitive inhibitors of NO synthesis have
been identified; Ng-monomethylarginine (L-NMMA) and Ng-Ng-
dimethylarginine (ADMA) and their contribution to the mainte-
nance of basal vascular tone have been demonstrated.11 Both
L-NMMA and ADMA are found in the plasma and urine of
healthy individuals and are altered in those with several diseases,
including renal failure, hypercholesterolemia, and atherosclero-
sis.12–14 We15 and others16 have shown that the plasma concen-
tration of ADMA drops early in normal pregnancy (hyperestro-
genic state) but is elevated in preeclampsia. L-NMMA and
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ADMA, but not symmetric dimethylarginine (SDMA), are
metabolized to citrulline by dimethylarginine dimethylaminohy-
drolase (DDAH), which is present in several tissues and cells
that synthesize NO, including endothelial cells.17,18
The following study was performed to test the hypothesis that
estrogens can regulate the concentration of ADMA through
changes in DDAH enzymatic activity. We propose that this may
be one mechanism by which estrogens exert their cardiovascular
effects.
Methods
Effect of Subcutaneous Ethynylestradiol Implant
on Plasma Methylarginine Concentration
Fifteen postmenopausal women attending outpatient clinics at St
George’s Hospital were chosen at random and gave informed, verbal
consent for blood sampling. None had received ERT before the
study. All were healthy and were not taking any medication for blood
pressure. At the time of recruitment, their average age, blood
pressure, and plasma cholesterol was 55.31.5 years, 1234.0/
75.82.3 mm Hg, and 5.580.334 mmol/L, respectively. Their diet
was unrestricted, and samples were taken immediately before and 2
weeks after the insertion of a 100-mg ethynylestradiol implant into
subcutaneous fat of the abdominal wall. Blood was taken by
venipuncture for the subsequent determination of methylarginines.
Serum estradiol concentration was determined by the Department of
Clinical Biochemistry using an enzyme-linked immunosorbent
assay.
Isolation and Measurement of Dimethylarginines
Quantitation of dimethylarginines was achieved by HPLC using the
method described previously.15 Concentrations of ADMA and
SDMA in the samples were determined by comparison with authen-
tic standards. Extraction efficiency was determined by the addition
of 10 g L-NMMA to each sample before extraction.
Cell Culture
In this study, we used the human umbilical vein endothelial cell line
SGHEC-7 and the murine endothelial cell line sEnd-1. Both exhibit
an endothelial cell phenotype and have been characterized and used
in several studies of ADMA and DDAH biology.17,19–21 The cells
were cultured as previously described.19,22 For experimental pur-
poses, estrogen was removed from the serum by overnight incuba-
tion with 0.2% (wt/vol) charcoal and 0.02% (wt/vol) dextran, stirring
constantly, at 4°C. This was then added to phenol red-free medium,
which was otherwise identical in composition to the normal growth
medium.
Effect of 17-Estradiol on the Release of
Dimethylarginines by Endothelial Cells in Culture
SGHEC-7 or sEnd-1 cells were seeded at a density of 2.5105
cells/mL, 10 mL per 90-mm culture dish, and maintained for 24
hours under standard incubation conditions. After washing with PBS,
the cells were incubated in estrogen-depleted, phenol red–free
medium. After 72 hours, the medium was replaced with identical
medium containing varying concentrations of 17-estradiol or eth-
anol as a vehicle control. In selected experiments, the effect of the
estrogen receptor antagonists tamoxifen and ICI 182780 or their
vehicle methanol on dimethylarginine release was investigated. At
the end of the incubation period, the culture supernatant was
removed and the methylarginines were determined as above. The
cells were washed with PBS, and the protein content was determined
by the Bradford assay (Bio-Rad).
Effect of 17-Estradiol on DDAH Activity
SGHEC-7 cells were seeded into 24-well plates (105 cells/mL, 0.5
mL/well) and cultured as above. The cells were washed, and 0.4 mL
medium containing 17-estradiol (final concentration, 1014 to 108
mol/L) was added to each well. The medium was removed after 24
hours, and cells were incubated with 0.25 mL Krebs solution
containing 14C-L-NMMA (0.04 Ci/mL) alone or with either
ADMA (3 mmol/L) or SDMA (3 mmol/L) for 1 hour at 37°C. Cells
were then washed twice with ice-cold PBS and lysed with sodium
dodecyl sulfate (SDS; 0.1% [wt/vol]; 0.4 mL). The lysate was added
to 1 mL of Dowex 50X8-400 resin, and 14C-citrulline was determined
by liquid scintillation counting.
Determination of DDAH, Estrogen Receptor-,
and Estrogen Receptor- Protein Expression
For the detection of DDAH, sEnd-1 cells were seeded into 90-mm
plates in standard medium and cultured as above. After 24 hours,
cells were washed with PBS and incubated in estrogen-depleted,
phenol red–free medium for 72 hours. The medium was replaced
with identical medium containing 17-estradiol (final concentration,
1014 to 108 mol/L), which was added for 24 hours. After this time,
protein isolation, electrophoresis, and western blot analysis were
carried out. The protein concentration was determined before load-
ing. Detection of membrane-bound antibodies was carried out using
enhanced chemiluminescence (Boehringer Mannheim). For the de-
tection of the estrogen receptors, confluent plates of SGHEC-7,
sEND-1, and human umbilical vein endothelial cells were used.19,22
Antibodies to estrogen receptor- (ER-) and ER- were obtained
from Santa Cruz. DDAH-I monoclonal antibody was a gift from Dr
Kimoto.23
Data Analysis
Data obtained from cell culture experiments were analyzed using the
nonparametric Mann-Whitney U test. The Student’s t test was used
for statistical analysis of clinical data. Statistical significance was
assumed at P0.05.
Results
Effect of 17-Estradiol Implants on Plasma
Dimethylarginine Concentration In Vivo
Fifteen postmenopausal women (mean age, 55.3 years; range,
46 to 63) allowed venipuncture immediately before and 2
weeks after the insertion of a 100-mg ethynylestradiol im-
plant. Before implant, the meanSEM serum estradiol con-
centration was 0.6930.075 nmol/L, whereas after implant
there was a small but significant increase to 0.8100.087
nmol/L (Figure 1, P0.05 as determined by Student’s t test).
The mean plasma ADMA concentration decreased from a
meanSEM of 0.7220.04 mol/L to 0.5880.03 mol/L
(P0.05). Although there was an apparent drop in the mean
plasma SDMA concentration after treatment with 17-
estradiol, this did not reach statistical significance
(0.4860.07 mol/L SEM compared with 0.3950.14
mol/L; P0.54).
Endothelial Estrogen Receptor Expression
Western blot analysis showed the expression of both ER-
and ER- by SGHEC-7 and sEnd-1 cells. Primary human
umbilical endothelial cells, which were used as a positive
control for the expression of the receptors (Figure 2).
Effect of 17-Estradiol on Dimethylarginine
Accumulation in Endothelial Cell Cultures
Stimulation of SGHEC-7 cells with 17-estradiol (1014 to
108 mol/L) significantly reduced the concentration of
ADMA in the medium by a maximum of 65.723.6%. At
1010mol/L, compared with control cultures (P0.001; Fig-
ure 3A), the concentration of SDMA was unaffected (data not
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shown). Using sEnd-1 cells, a similar dose-dependent reduc-
tion in the concentration of ADMA was seen in the culture
supernatant (Figure 3B). Changes in the release of ADMA
were not detected at earlier time points.
Effect of Tamoxifen on the Accumulation of
Dimethylarginines in Endothelial Cell Cultures
In the presence of 1014 mol/L 17-estradiol, there was a
significant reduction in the ADMA concentration of the
culture supernatant from SGHEC-7 cells, as seen previously
(Figure 4). Under these conditions, tamoxifen at 108 mol/L
inhibited the reduction in ADMA concentration associated
with 1014 mol/L 17-estradiol (8316%, P0.01); the
methanol control had no effect. In the presence of tamoxifen,
the effect of 17-estradiol on ADMA was not significantly
different from control. A similar inhibitory effect could also
be demonstrated after the incubation of sEnd-1 cells with
tamoxifen (data not shown).
Neither tamoxifen nor its vehicle methanol had any effect on
the concentration of SDMA in the culture supernatant (data not
shown). Neither ethanol nor methanol had any effect on dim-
ethylarginine accumulation in SGHEC-7 cell culture superna-
tants at concentrations up to 10-fold higher than those used in
these experiments. The specific high-affinity estrogen receptor
antagonist ICI 182780 was also able to partially inhibit the
effects of 17-estradiol (17-estradiol ADMA as a percent of
control, 42.8912, n5; compared with 17-estradiol plus ICI
182780, 87.413%, n5; P0.05).
Effect of 17-Estradiol on DDAH Activity
DDAH activity in SGHEC-7 cells was stimulated by 17-
estradiol (1014 and 108 mol/L) as determined by the
production of 14C-citrulline by 236.3% (P0.01) and
355.3% (P0.001), respectively (Figure 5A). This activity
was inhibited by tamoxifen. Cells incubated with tamoxifen
in the absence of 17-estradiol showed a small increase in
DDAH activity, although this did not reach statistical signif-
icance (data not shown). The DDAH-specific conversion of
14C-L-NMMA to 14C-citrulline was investigated, and the
results from a representative assay are shown in Figure 5B.
The production of 14C-citrulline was inhibited by the addition
of 3 mol/L ADMA to the assay from 13.82.4 to 0.890.7
pmol citrulline per min per mg cell protein (P0.001). The
Figure 1. Plasma concentration of 17-estradiol and ADMA.
Blood was taken from 15 postmenopausal women just before
and 2 weeks after the subcutaneous insertion of a 100-mg
estradiol implant. The circulating concentrations of 17-estradiol
(A) and ADMA (B) are expressed as meanSEM before and
after implant as measured by ELISA and HPLC, respectively.
Data analysis was by 2-tailed t test. *P0.05.
Figure 2. Estrogen receptor expression. Untreated cell lysates
were subjected to Western blot analysis. Lane 1, SGHEC-7
cells; lane 2, sEnd-1 cells; lane 3, primary human umbilical vein
endothelial cells. Separate blots were probed for ER- (panel A;
49.5 g/well) and ER- (panel B; 34.5 g/well).
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addition of 3 mmol/L SDMA had no effect on 14C-citrulline
production.
Effect of 17-Estradiol on DDAH-I
Protein Expression
Having established that 17-estradiol increased DDAH ac-
tivity in both SGHEC-7 and sEnd-1 cells, we used sEnd-1
cells to determine whether DDAH-I protein expression was
altered after stimulation. The use of murine cells in this
experiment overcame poor species cross-reactivity previously
reported when using the monoclonal antibody raised against
rat DDAH-I.17,23 Stimulation with 17-estradiol up to 108
mol/L had no effect on DDAH-I expression in these cells
(Figure 6).
Discussion
The significant findings of this investigation are the follow-
ing: (1) circulating ADMA is reduced in women after ERT;
(2) in vitro, estrogen reduces the release of ADMA by
endothelial cells; (3) estrogen stimulates endothelial cell
DDAH enzyme activity; (4) both the inhibition of the release
of ADMA and the increased DDAH activity are inhibited by
estrogen receptor antagonists; and (5) increased DDAH
activity was not attributable to increased expression of
DDAH I.
There has been considerable interest in the regulation of
cardiovascular function by estrogen and in particular how
estrogens may regulate the production of NO. Mechanistic
studies demonstrate the ability of estrogens to increase the
bioavailability of NO by directly stimulating changes in the
expression of eNOS or through indirect regulation of genes
encoding essential cofactors. In addition, estrogen may alter NO
synthesis via its direct antioxidant effects.24 We examined
whether estrogen could also regulate the concentration of
ADMA, an endogenous inhibitor of NO synthesis.
Previous studies have shown that ADMA is synthesized by
and released from endothelial cells in culture.19,25 It competes
with arginine for both the active site of NOS and the Y
transporter.21,26 Significantly, the intracellular concentration of
ADMA can reach 5 times that of the extracellular or circulating
concentration. At this concentration, inhibition of NOS is a
possibility.27 Therefore, manipulation of intracellular or the
circulating concentration of ADMA could regulate both basal
and stimulated NO synthesis. In support of this hypothesis,
inhibiting ADMA metabolism in isolated vascular rings induced
contraction, which could be reversed by L-arginine.17 More
recently, a role for ADMA as a marker of cardiovascular disease
has been proposed,28 and significant correlation between the
circulating concentration of ADMA and intima-media thicken-
ing in the carotid artery and impaired endothelium-dependent
relaxation has been found.29 We have shown during normoten-
sive pregnancies (a hyperestrogenic state) that an early drop in
Figure 3. Effect of 17-estradiol on the release of dimethylargin-
ine by endothelial cells in culture. 17-estradiol was added to
SGHEC-7 (A) and sEnd-1 (B) cells for 24 hours. The concentra-
tion of ADMA and SDMA was determined by HPLC. Results
were normalized in each experiment by taking the mean ADMA
concentration for cells in phenol red–free, estrogen-deplete
medium as 100%. Results are presented as meanSEM of 3
independent experiments carried out in triplicate. Comparisons
were made with ethanol vehicle control using Mann-Whitney U
analysis; **P0.01, ***P0.001.
Figure 4. Effect of estrogen receptor antagonists on ADMA
accumulation in the culture supernatant of SGHEC-7 cells. Cells
were incubated with either vehicle alone or tamoxifen17-
estradiol. The results were normalized in each experiment by
taking the mean ADMA concentration in untreated cells as
100%. The results presented are meanSEM from 2 indepen-
dent experiments carried out in triplicate; **P0.01.
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blood pressure correlated with a significant fall in plasma
ADMA concentration.15
Increased NO synthesis after the administration of estradiol
has been demonstrated.7 In premenopausal women, plasma NO
peaks midcycle, when estrogen reaches its maximum circulating
concentration.30 Administration of estradiol to postmenopausal
women induced a sustained increase in NO production,31
whereas increased expression of eNOS mRNA and enhanced
calcium-dependent NOS activity has been reported in animals.32
Contrary to expectations, the serum ADMA concentration of
our sample group before treatment was not significantly differ-
ent from our previous report, in which 20 healthy young
nonpregnant women were studied.15 However, there was a
significant reduction in the plasma concentration of ADMA after
estradiol implantation. Our failure to detect any change in the
concentration of SDMA would be predicted after the specific
activation of DDAH by estrogen. Although the limited nature of
the study group restricts the extent of the interpretation, this
study is in agreement with a recent study indicating a reduction
in circulating ADMA in postmenopausal women undergoing
ERT.33 The magnitude of the fall in ADMA in response to a
modest rise in estradiol probably reflects the sensitivity of
endothelial cells to 17-estradiol, which is supported by our in
vitro studies.
To examine the mechanism at a cellular level, experiments
were performed using 2 endothelial cell models, which express
both ER- and ER-. In both cell types, stimulation with
physiological concentration of 17-estradiol significantly re-
duced the concentration of ADMA. The involvement of the
estrogen receptor was investigated using receptor antagonists.
Tamoxifen, which inhibits estrogen-induced NO synthesis by
endothelial cells,34 significantly increased endothelial cell
ADMA concentrations. Consistent with mixed agonist/antago-
nist activity, 1011 mol/L tamoxifen alone reduced the accumu-
lation of ADMA but not SDMA (data not shown). In this regard,
it is interesting to speculate that a reduction in the circulating
concentration of ADMA may contribute to the cardioprotective
effects observed in some groups undergoing cancer treatment
with tamoxifen.35 We were able to confirm the involvement of
estrogen receptors by the use of ICI 182780, which, like
tamoxifen, was able to partially inhibit the fall in ADMA
observed with 17-estradiol treatment.
The active metabolism of ADMA and L-NMMA, but not
SDMA or L-arginine, to citrulline and methylamines by DDAH
has been described in vascular endothelial cells.17 The differen-
tial effect of estradiol on ADMA but not SDMA observed in
vivo in this study would indicate a specific change in ADMA
metabolism, perhaps by alterations in DDAH activity. This
involvement could be confirmed, because treatment with 17-
estradiol significantly increased DDAH activity in vitro. How-
ever, the exact mechanism for this is unknown. Two isoforms of
DDAH have been identified.18 Whereas a change in DDAH-I
expression was not detected, in this study, undetected changes in
DDAH-II protein expression may in part be responsible for the
increased DDAH activity observed. The expression of DDAH-II
was examined using recently available commercial antibodies;
however, these proved unsatisfactory both in the detection of
DDAH-II from test samples as well as recombinant DDAH II.
Alternatively, 17-estradiol may act as an antioxidant, because
oxidative stress can inhibit DDAH without affecting DDAH
expression.36
Figure 5. Effect of 17-estradiol on DDAH enzyme activity. A,
SGHEC-7 cells were stimulated with 17-estradiol for 24 hours.
DDAH activity was determined by the conversion of 14C-L-
NMMA to citrulline. The production of 14C-citrulline is normalized
to that of unstimulated control cells. Results presented are
meanSEM of n12 determinations from 3 independent experi-
ments. Significance was determined using Mann-Whitney U
test; **P0.01, ***P0.001. B, DDAH-specific conversion of 14C-
L-NMMA to 14C-citrulline was investigated, and the results from
a representative assay are shown. Cells were treated as above
but were incubated in the presence and absence of either
3 mmol/L ADMA or 3 mmol/L SDMA. Results are meanSEM of
n8 determinations from a representative experiment. Signifi-
cance was determined using Mann-Whitney U test; ***P0.001.
Figure 6. Effect of 17-estradiol on DDAH-I expression. sEnd-1
cells were stimulated with 17-estradiol (final concentration,
1014 to 108 mol/L) and subjected to western blot analysis.
Lanes 1 and 2 show control, unstimulated cells; lanes 3 and 4
show 108 mol/L; lanes 5 and 6 show 1011 mol/L; lane 7 shows
1014 mol/L 17-estradiol; and lanes 8 and 9 show a positive
control of rat glioma cells transfected to overexpress DDAH I.
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Two large randomized studies, one of healthy post meno-
pausal women and the other of postmenopausal women with
preexisting cardiovascular disease, found significant adverse
cardiovascular effects after the combined use of estrogen and
progesterone therapy2,3 despite significant advantageous
changes in the lipid profiles compared with placebo group.3
However, because neither study was designed to determine the
effects of estrogen alone, direct comparison with the present
study is not possible. It is interesting to speculate how adminis-
tration of progesterone might interact with estradiol to regulate
DDAH activity and, therefore, ADMA accumulation.
In conclusion, we have demonstrated that 17-estradiol
decreases the circulating concentration of ADMA in vivo
and release from endothelial cells in vitro, the latter
because of increased DDAH activity. These results may in
part explain increased NO synthesis observed in women
undergoing hormonal replacement therapy and therefore
could contribute to some of the cardiovascular effects
attributed to estrogens.
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